1717 K Street NW, Suite 900

Washington, DC 20006-5349

(877) 363-6376

HELPLINE

mesothelioma research

FDA Approves KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Patients with Unresectable or Metastatic Malignant Pleural Mesothelioma

For patients with MPM (Malignant Pleural Mesothelioma), the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) as a first-line treatment when combined with pemetrexed and platinum-based chemotherapy. Keytruda(pembrolizumab) is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help…

Treatment and therapies for peritoneal mesothelioma

Peritoneal mesothelioma can be treated surgically (i.e. HIPEC) and/or systemically (chemotherapy or immunotherapy). This session features two medical oncologists and three peritoneal mesothelioma surgeons as they discuss a number of case scenarios and considerations when choosing a treatment.This session features:  Kiran Turaga, MD, Yale Andrew Blakeley, MD, NIHGarrett Nash, MD,…